Study Evaluating Enbrel (Etanercept) in Adult Patients With Plaque Psoriasis
Information source: Wyeth
Information obtained from ClinicalTrials.gov on February 12, 2009
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Plaque Psoriasis
Intervention: Enbrel (Drug)
Phase: N/A
Status: Recruiting
Sponsored by: Wyeth Official(s) and/or principal investigator(s):
Medical Monitor, Study Director, Affiliation: Wyeth
Trial Manager, Principal Investigator, Affiliation: MedinfoDEU@wyeth.com
Overall contact:
Trial Manager, Email: clintrialparticipation@wyeth.com
Summary
The purpose of this study is to investigate the incidences of adverse events for patients
with plaque psoriasis treated with Enbrel under usual care settings.
Clinical Details
Official title: Observational Study With Enbrel (Etanercept) in Adult Patients With Plaque Psoriasis
Study design: Cohort, Prospective
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Proven diagnosis of Plaque Psoriasis
Exclusion Criteria:
- Contraindications according to SmPC of Enbrel
Locations and Contacts
Trial Manager, Email: clintrialparticipation@wyeth.com
Bonn, Nordrheim-Westfalen 53105, Germany; Recruiting
Additional Information
Starting date: April 2005
Ending date: April 2009
Last updated: December 19, 2007
|
